← Back to all trials
Enrolling By Invitation
NCT06285071
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
Conditions: Haemophilia A, Haemophilia B
Sex: All
Healthy volunteers: No
Enrollment: 23
Sponsor: Novo Nordisk A/S
Location: Novo Nordisk Investigational Site Toshima City Tokyo
Summary
The purpose of the study is to investigate the safety and effectiveness of Alhemo® in all participants under real-world clinical practice in Japan. Participants will get Alhemo® as prescribed by the study doctor. The study will last for about 2 years.
Eligibility Criteria
Inclusion Criteria:
* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
* The decision to initiate treatment with commercially available Alhemo® has been made by the patient/LAR and the treating physician before and independently from the decision to include the patient in this study
* Male or female patients, regardless of age
* Diagnosis with HAwI/HBwI
Exclusion Criteria:
\- Previous participation in this study. Participation is defined as having given informed consent in this study
Source: ClinicalTrials.gov (NCT06285071). StuddyBuddy aggregates publicly available trial information.
